Professional Summary
Professional Overview
Jan Rosenbaum is an accomplished executive and scientist with extensive experience in the pharmaceutical and biotechnology industries. As the President, Chief Executive Officer, and Chief Scientific Officer at Kurome Therapeutics, Inc., he leverages his deep expertise in drug development, business strategy, and scientific innovation to drive the company's growth and therapeutic advancements.
Experience Summary
Current Role
As the President, CEO, and CSO of Kurome Therapeutics, Inc., Jan is responsible for overseeing the company's strategic direction, managing day-to-day operations, and leading the scientific research and development efforts. Under his leadership, Kurome Therapeutics has made significant progress in advancing its pipeline of novel therapeutics, with a focus on addressing unmet medical needs.
In addition to his role at Kurome Therapeutics, Jan serves as a Business Development Advisor for the Therapeutics Development Team at the Harrington Discovery Institute at University Hospitals, where he provides strategic guidance and expertise to support the translation of academic discoveries into viable drug candidates.
Career Progression
Prior to his current positions, Jan held several notable roles, including Chief Scientific Officer at Airway Therapeutics, Executive-in-Residence at CincyTechUSA and CincyTech, and Principal Scientist at Procter & Gamble Pharmaceuticals. During his tenure at these organizations, he played a pivotal role in driving scientific advancements, fostering collaborations, and contributing to the development of innovative pharmaceutical products.
Academic Background
Jan Rosenbaum holds a Ph.D. in Pharmaceutical Sciences from Stanford University School of Medicine, where he completed his postdoctoral fellowship. His specialized expertise and academic achievements have positioned him as a respected thought leader in the industry.
Areas of Expertise
- Drug discovery and development
- Translational research and clinical trial design
- Pharmaceutical industry strategy and business development
- Scientific leadership and team management
- Collaborations and partnerships with academic institutions and industry partners
Professional Impact
Throughout his distinguished career, Jan has made significant contributions to the pharmaceutical and biotechnology sectors. He has led the development of multiple drug candidates, several of which have advanced to late-stage clinical trials or received regulatory approvals. Additionally, his extensive experience in scientific research, industry collaboration, and business strategy has enabled him to drive meaningful progress in the translation of academic discoveries into viable therapeutic solutions.
Conclusion
With his proven track record of success, Jan Rosenbaum is a seasoned executive and scientific leader who continues to shape the future of the pharmaceutical industry. His expertise, strategic vision, and commitment to innovation position him as a valuable asset to Kurome Therapeutics and the broader life sciences community.
